Hengyu Biopharmaceutical (Shandong) Co., Ltd. has set up a PDRN medical research center and a PDRN specialized research laboratory in the national high-tech zone, which is a project of Shandong International Biotechnology Park.

We will create a PDRN medical research, development and shared application model with an international dimension together with the School of Pharmacy of Peking University, the Coastal Zone Research Institute of the Chinese Academy of Sciences, the Qingdao National Laboratory of Marine Science and Technology Pilot, Dankook University (South Korea) and several biopharmaceutical enterprises and institutions in South Korea. A complete and comprehensive scientific research service system has been provided, including marine ribonucleic acid PDRN/PN major subject research, international/domestic industry access, medical research and product development and application, cutting-edge biotechnology and regenerative medicine, medical beauty research, etc., which can boost the research and development and application process of PDRN/PN in China, and provide technical support for the development of China's marine nucleic acid industry.

       Hengyu Biopharmaceutical (Shandong) Co., Ltd. has established an international professional research team of nucleic acid drug research PDRN/PN with national high-level talents and experts as the core backbone.

      In 2019, the laboratory improved the extraction process with cutting-edge technology in the industry, and successfully extracted the medical grade renewable substance PDRN from salmon, with an extraction rate of 20%, which was far higher than the extraction level of 7% of similar competitive companies in the world at that time, the laboratory also obtained several national patents including national invention patents, and carried out innovative designs such as formula research and development, trial production and verification of different effects around PDRN/PN and finally has built an independent intellectual property system.